Global Phase 2b/3 Trial: Atom Bioscience Recruits US Patients for Chronic Gout Treatment

Innovative pharmaceutical company Atom Bioscience, established in 2012, is dedicated to the development of superior oral small molecule drugs for the treatment of metabolic and inflammatory diseases, including acute and chronic gout. The company's leading product, ABP-671, is undergoing pivotal clinical trials and has demonstrated promising therapeutic effects, safety, and tolerability in previous studies. Additionally, ABP-745, another molecule developed for anti-inflammatory autoimmune conditions, has shown positive results in preclinical trials and is now entering Phase 1 clinical trials for acute gout.
Atom Bioscience's recent announcement highlights the appointment of Mr. Hu Xianjun as the Vice President of Clinical Affairs, effective April 16, 2024. Mr. Hu will be responsible for overseeing clinical operations in China, marking a significant step in the company's growth and commitment to advancing medical solutions for patients worldwide.
A clinical study in the United States is currently recruiting participants aged 19-69 who have been diagnosed with gout. The study aims to assess the efficacy and safety of a new treatment option for this debilitating condition. Eligible participants without a history of rheumatoid arthritis or other autoimmune diseases may receive compensation for their time and travel. This research could potentially offer relief to millions suffering from gout, a form of inflammatory arthritis caused by elevated levels of serum uric acid, which can severely impact the quality of life and even increase the risk of sudden cardiac death.
Existing treatments for chronic gout have been criticized for their limited effectiveness and concerning safety profiles, with risks including kidney failure, sudden cardiac death, and severe liver toxicity. Atom Bioscience's efforts to develop safer and more effective therapies address a significant unmet medical need, offering hope to patients and healthcare providers alike.
The company's focus on innovation and excellence is evident in its commitment to creating best-in-class therapeutics. With a robust pipeline and a team of experienced professionals, Atom Bioscience is well-positioned to make a substantial impact on the treatment landscape for metabolic and inflammatory diseases.